Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• Have persistent facial erythema on the cheeks of at least moderate severity.

• Women must not be able to bear children

Exclusion Criteria:

• Have more than 12 inflammatory lesions on the face

• Previous treatment of facial skin with lasers or electrocauterisation within 2 months prior to entering the study

• Have facial hair that makes it difficult to evaluate rosacea on the face Other protocol-defined inclusion/exclusion criteria may apply